Skip to main content
Top
Published in: Cellular Oncology 1/2019

01-02-2019 | Original Paper

CCL18 secreted from M2 macrophages promotes migration and invasion via the PI3K/Akt pathway in gallbladder cancer

Authors: Zhenyu Zhou, Yaorong Peng, Xiaoying Wu, Shiyu Meng, Wei Yu, Jinghua Zhao, Heyun Zhang, Jie Wang, Wenbin Li

Published in: Cellular Oncology | Issue 1/2019

Login to get access

Abstract

Purpose

The presence of M2 macrophages within primary tumors has been correlated with a poor prognosis for many types of cancer. However, little is known about the role of M2 macrophages in gallbladder cancer (GBC).

Methods

The number of M2 macrophages in 78 GBC and 16 normal gallbladder tissue samples was assessed by immunohistochemistry. The THP-1 monocyte cell line was differentiated into M2 macrophages and co-cultured with GBC-derived cell lines. The effect of M2 macrophages on promoting GBC cell migration and invasion was analyzed using migration, invasion and scratch wound healing assays. Western blotting and real-time PCR were used to assess the expression of epithelial-mesenchymal transition (EMT) markers and the activation status of the PI3K/Akt signaling pathway in GBC cells co-cultured with THP-1-derived macrophages.

Results

The average number of M2 macrophages was found to be significantly higher in GBC tissues than in normal gallbladder tissues. We also found that GBC patients with higher M2 macrophage counts exhibited poorer overall survival rates. Co-culture with M2 macrophages significantly promoted the migration, invasion and EMT of GBC cells. Moreover, we found that CCL18 secreted from M2 macrophages had the same effect on GBC cells as M2 macrophages. Blocking the function of CCL18 with a neutralizing antibody reversed this effect. Finally, we found that M2 macrophages could activate PI3K/Akt signaling in GBC cells, thereby leading to migration, invasion and EMT of these cells.

Conclusions

Our findings contribute to our understanding of the role of chronic inflammation in GBC development and progression, and may offer potential therapeutic targets for GBC.
Appendix
Available only for authorised users
Literature
1.
go back to reference A.X. Zhu, T.S. Hong, A.F. Hezel, D.A. Kooby, Current management of gallbladder carcinoma. Oncologist 15, 168–181 (2010)CrossRef A.X. Zhu, T.S. Hong, A.F. Hezel, D.A. Kooby, Current management of gallbladder carcinoma. Oncologist 15, 168–181 (2010)CrossRef
2.
go back to reference W. Jung, J.Y. Jang, M.J. Kang, Y.R. Chang, Y.C. Shin, J. Chang, S.W. Kim, Effects of surgical methods and tumor location on survival and recurrence patterns after curative resection in patients with T2 gallbladder cancer. Gut Liver 10, 140–146 (2016)CrossRef W. Jung, J.Y. Jang, M.J. Kang, Y.R. Chang, Y.C. Shin, J. Chang, S.W. Kim, Effects of surgical methods and tumor location on survival and recurrence patterns after curative resection in patients with T2 gallbladder cancer. Gut Liver 10, 140–146 (2016)CrossRef
4.
go back to reference Y. Li, J. Zhang, H. Ma, Chronic inflammation and gallbladder cancer. Cancer Lett 345, 242–248 (2014)CrossRef Y. Li, J. Zhang, H. Ma, Chronic inflammation and gallbladder cancer. Cancer Lett 345, 242–248 (2014)CrossRef
5.
go back to reference X.S. Wu, L.B. Shi, M.L. Li, Q. Ding, H. Weng, W.G. Wu, Y. Cao, R.F. Bao, Y.J. Shu, Q.C. Ding, J.S. Mu, J. Gu, P. Dong, Y.B. Liu, Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol 21, 449–457 (2014)CrossRef X.S. Wu, L.B. Shi, M.L. Li, Q. Ding, H. Weng, W.G. Wu, Y. Cao, R.F. Bao, Y.J. Shu, Q.C. Ding, J.S. Mu, J. Gu, P. Dong, Y.B. Liu, Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol 21, 449–457 (2014)CrossRef
6.
go back to reference S.M. Crusz, F.R. Balkwill, Inflammation and cancer: Advances and new agents. Nat Rev Clin Oncol 12, 584–596 (2015)CrossRef S.M. Crusz, F.R. Balkwill, Inflammation and cancer: Advances and new agents. Nat Rev Clin Oncol 12, 584–596 (2015)CrossRef
7.
go back to reference A. Kuraishy, M. Karin, S.I. Grivennikov, Tumor promotion via injury- and death-induced inflammation. Immunity 35, 467–477 (2011)CrossRef A. Kuraishy, M. Karin, S.I. Grivennikov, Tumor promotion via injury- and death-induced inflammation. Immunity 35, 467–477 (2011)CrossRef
8.
go back to reference P. Nilendu, S.C. Sarode, D. Jahagirdar, I. Tandon, S. Patil, G.S. Sarode, J.K. Pal, N.K. Sharma, Mutual concessions and compromises between stromal cells and cancer cells: Driving tumor development and drug resistance. Cell Oncol 41, 353–367 (2018)CrossRef P. Nilendu, S.C. Sarode, D. Jahagirdar, I. Tandon, S. Patil, G.S. Sarode, J.K. Pal, N.K. Sharma, Mutual concessions and compromises between stromal cells and cancer cells: Driving tumor development and drug resistance. Cell Oncol 41, 353–367 (2018)CrossRef
9.
go back to reference I.A. Voutsadakis, Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: Therapeutic implications. Cell Oncol 41, 107–121 (2018)CrossRef I.A. Voutsadakis, Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: Therapeutic implications. Cell Oncol 41, 107–121 (2018)CrossRef
10.
go back to reference S. Oguro, Y. Ino, K. Shimada, Y. Hatanaka, Y. Matsuno, M. Esaki, S. Nara, Y. Kishi, T. Kosuge, N. Hiraoka, Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci 106, 1750–1760 (2015)CrossRef S. Oguro, Y. Ino, K. Shimada, Y. Hatanaka, Y. Matsuno, M. Esaki, S. Nara, Y. Kishi, T. Kosuge, N. Hiraoka, Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci 106, 1750–1760 (2015)CrossRef
11.
go back to reference S. Su, Q. Liu, J. Chen, J. Chen, F. Chen, C. He, D. Huang, W. Wu, L. Lin, W. Huang, Z. J, X. Cui, F. Zheng, H. Li, H. Yao, F. Su, E. Song, A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25, 605–620 (2014)CrossRef S. Su, Q. Liu, J. Chen, J. Chen, F. Chen, C. He, D. Huang, W. Wu, L. Lin, W. Huang, Z. J, X. Cui, F. Zheng, H. Li, H. Yao, F. Su, E. Song, A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25, 605–620 (2014)CrossRef
12.
go back to reference X. Ye, R.A. Weinberg, Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol 25, 675–686 (2015)CrossRef X. Ye, R.A. Weinberg, Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol 25, 675–686 (2015)CrossRef
13.
go back to reference O.W. Yeung, C.M. Lo, C.C. Ling, X. Qi, W. Geng, C.X. Li, K.T. Ng, S.J. Forbes, X.Y. Guan, R.T. Poon, S.T. Fan, K. Man, Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol 62, 607–616 (2015)CrossRef O.W. Yeung, C.M. Lo, C.C. Ling, X. Qi, W. Geng, C.X. Li, K.T. Ng, S.J. Forbes, X.Y. Guan, R.T. Poon, S.T. Fan, K. Man, Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol 62, 607–616 (2015)CrossRef
14.
go back to reference C.Y. Liu, J.Y. Xu, X.Y. Shi, W. Huang, T.Y. Ruan, P. Xie, J.L. Ding, M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Investig 93, 844–854 (2013)CrossRef C.Y. Liu, J.Y. Xu, X.Y. Shi, W. Huang, T.Y. Ruan, P. Xie, J.L. Ding, M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. Lab Investig 93, 844–854 (2013)CrossRef
15.
go back to reference T. Kitamura, B.Z. Qian, J.W. Pollard, Immune cell promotion of metastasis. Nat Rev Immunol 15, 73–86 (2015)CrossRef T. Kitamura, B.Z. Qian, J.W. Pollard, Immune cell promotion of metastasis. Nat Rev Immunol 15, 73–86 (2015)CrossRef
16.
go back to reference J. Chen, Y. Yao, C. Gong, F. Yu, S. Su, J. Chen, B. Liu, H. Deng, F. Wang, L. Lin, H. Yao, F. Su, K.S. Anderson, Q. Liu, M.E. Ewen, X. Yao, E. Song, CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19, 541–555 (2011)CrossRef J. Chen, Y. Yao, C. Gong, F. Yu, S. Su, J. Chen, B. Liu, H. Deng, F. Wang, L. Lin, H. Yao, F. Su, K.S. Anderson, Q. Liu, M.E. Ewen, X. Yao, E. Song, CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19, 541–555 (2011)CrossRef
17.
go back to reference S.Y. Lee, E.K. Jeong, M.K. Ju, H.M. Jeon, M.Y. Kim, C.H. Kim, H.G. Park, S.I. Han, H.S. Kang, Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer 16, 10 (2017)CrossRef S.Y. Lee, E.K. Jeong, M.K. Ju, H.M. Jeon, M.Y. Kim, C.H. Kim, H.G. Park, S.I. Han, H.S. Kang, Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer 16, 10 (2017)CrossRef
18.
go back to reference L. Larue, A. Bellacosa, Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24, 7443–7454 (2005)CrossRef L. Larue, A. Bellacosa, Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24, 7443–7454 (2005)CrossRef
19.
go back to reference A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, P. Allavena, Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14, 399–416 (2017)CrossRef A. Mantovani, F. Marchesi, A. Malesci, L. Laghi, P. Allavena, Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14, 399–416 (2017)CrossRef
20.
go back to reference J.A. Espinoza, C. Bizama, P. García, C. Ferreccio, M. Javle, J.F. Miquel, J. Koshiol, J.C. Roa, The inflammatory inception of gallbladder cancer. Biochim Biophys Acta 1865, 245–254 (2016)PubMedPubMedCentral J.A. Espinoza, C. Bizama, P. García, C. Ferreccio, M. Javle, J.F. Miquel, J. Koshiol, J.C. Roa, The inflammatory inception of gallbladder cancer. Biochim Biophys Acta 1865, 245–254 (2016)PubMedPubMedCentral
21.
go back to reference R. Noy, J.W. Pollard, Tumor-associated macrophages: From mechanisms to therapy. Immunity 41, 49–61 (2014)CrossRef R. Noy, J.W. Pollard, Tumor-associated macrophages: From mechanisms to therapy. Immunity 41, 49–61 (2014)CrossRef
22.
go back to reference P. Italiani, D. Boraschi, From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation. Front Immuno l5, 514 (2014) P. Italiani, D. Boraschi, From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation. Front Immuno l5, 514 (2014)
23.
go back to reference L.M. Nusblat, M.J. Carroll, C.M. Roth, Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol 40, 471–482 (2017)CrossRef L.M. Nusblat, M.J. Carroll, C.M. Roth, Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol 40, 471–482 (2017)CrossRef
24.
go back to reference C. Ngambenjawong, H.H. Gustafson, S.H. Pun, Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114, 206–221 (2017)CrossRef C. Ngambenjawong, H.H. Gustafson, S.H. Pun, Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114, 206–221 (2017)CrossRef
25.
go back to reference G.K. Alderton, Metastasis: Epithelial to mesenchymal and back again. Nat Rev Cancer 13, 3 (2013)CrossRef G.K. Alderton, Metastasis: Epithelial to mesenchymal and back again. Nat Rev Cancer 13, 3 (2013)CrossRef
26.
go back to reference M. Suarez-Carmona, J. Lesage, D. Cataldo, C. Gilles, EMT and inflammation: Inseparable actors of cancer progression. Mol Oncol 11, 805–823 (2017)CrossRef M. Suarez-Carmona, J. Lesage, D. Cataldo, C. Gilles, EMT and inflammation: Inseparable actors of cancer progression. Mol Oncol 11, 805–823 (2017)CrossRef
27.
go back to reference D. Huang, S.J. Song, Z.Z. Wu, W. Wu, X.Y. Cui, J.N. Chen, M.S. Zeng, S.C. Su, Epstein-Barr virus-induced VEGF and GM-CSF drive nasopharyngeal carcinoma metastasis via recruitment and activation of macrophages. Cancer Res 77, 3591–3604 (2017)CrossRef D. Huang, S.J. Song, Z.Z. Wu, W. Wu, X.Y. Cui, J.N. Chen, M.S. Zeng, S.C. Su, Epstein-Barr virus-induced VEGF and GM-CSF drive nasopharyngeal carcinoma metastasis via recruitment and activation of macrophages. Cancer Res 77, 3591–3604 (2017)CrossRef
28.
go back to reference Z. Lin, W. Li, H. Zhang, W. Wu, Y. Peng, Y. Zeng, Y. Wan, J. Wang, N. Ouyang, CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-kappaB signaling pathway in hepatocellular carcinoma. Tumour Biol 37, 3461–3468 (2016)CrossRef Z. Lin, W. Li, H. Zhang, W. Wu, Y. Peng, Y. Zeng, Y. Wan, J. Wang, N. Ouyang, CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-kappaB signaling pathway in hepatocellular carcinoma. Tumour Biol 37, 3461–3468 (2016)CrossRef
29.
go back to reference R. Yuan, Y. Chen, X. He, X. Wu, J. Ke, Y. Zou, Z. Cai, Y. Zeng, L. Wang, J. Wang, X. Fan, X. Wu, P. Lan, CCL18 as an independent favorable prognostic biomarker in patients with colorectal cancer. J Surg Res 183, 163–169 (2013)CrossRef R. Yuan, Y. Chen, X. He, X. Wu, J. Ke, Y. Zou, Z. Cai, Y. Zeng, L. Wang, J. Wang, X. Fan, X. Wu, P. Lan, CCL18 as an independent favorable prognostic biomarker in patients with colorectal cancer. J Surg Res 183, 163–169 (2013)CrossRef
Metadata
Title
CCL18 secreted from M2 macrophages promotes migration and invasion via the PI3K/Akt pathway in gallbladder cancer
Authors
Zhenyu Zhou
Yaorong Peng
Xiaoying Wu
Shiyu Meng
Wei Yu
Jinghua Zhao
Heyun Zhang
Jie Wang
Wenbin Li
Publication date
01-02-2019
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 1/2019
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-018-0410-8

Other articles of this Issue 1/2019

Cellular Oncology 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine